📌 Basgenbio is proud to announce the recent publication of an Original Research Article using the Drug Efficacy Simulation Solution, DEEPCT (DEEP learning-based Clinical Trials), in the latest issue of the leading SCI journal, Scientific Reports.
📌 In this study, the effects of 'Xanthine Oxidase Inhibitors (XOIs)' on cardiovascular diseases were evaluated. XOIs, including allopurinol and febuxostat, have been used primarily for treating gout, as their antioxidative properties help reduce the production of reactive oxygen species. These antioxidative activities are expected to positively impact cardiovascular disease; however, the exact nature of this causality remains unknown.
📌 Our results indicate that urate reducers not only lower the risk of stroke but also hold potential in treating acute myocardial infarction, particularly in individuals with high serum triglyceride levels.
